← Leaderboards
Duane D Miller
University Of Tennessee Health Sci Ctr
$5,855,110
Attributed
$8,882,604
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $902.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,882,604 · 7
By mechanism
R01$6,446,018 · 3
R33$1,108,483 · 1
R21$777,900 · 2
U19$550,203 · 1
Top collaborators
- Wei Li12 shared
- Mostafa Waleed Gaber3 shared
- Lawrence M Pfeffer3 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Gabor J Tigyi$24,190,037
- John K. Buolamwini$5,902,126
- Wei Li$11,377,399
- Russell W. Chesney$1,525,307
- Mostafa Waleed Gaber$272,225
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogPharmaceutical PreparationsDrug KineticsCell LineIn VivoFutureIn VitroDoseTargeted TreatmentStructureBindingDrug UsageMalignant NeoplasmsPropertyGenerationsHematopoieticOralScaffoldGrantApoptosisBaseCellsGrowthToxic Effect
Grant awards (29)
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity$512,586
R01 · FY2025 · CA
Targeting the colchicine binding site in tubulin for cancer therapy$389,817
R01 · FY2025 · CA
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity$482,829
R01 · FY2024 · CA
Targeting the colchicine binding site in tubulin for cancer therapy$370,326
R01 · FY2024 · CA
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity$504,020
R01 · FY2023 · CA
Targeting the colchicine binding site in tubulin for cancer therapy$389,817
R01 · FY2023 · CA
Targeting the colchicine binding site in tubulin for cancer therapy$382,020
R01 · FY2022 · CA
Targeting the colchicine binding site in tubulin for cancer therapy$403,307
R01 · FY2021 · CA
Targeting the colchicine site in tubulin for advanced melanoma$365,493
R01 · FY2020 · CA
Targeting the colchicine site in tubulin for advanced melanoma$354,527
R01 · FY2019 · CA
Targeting the colchicine site in tubulin for advanced melanoma$365,493
R01 · FY2018 · CA
Targeting the colchicine site in tubulin for advanced melanoma$365,493
R01 · FY2017 · CA
Targeting the colchicine site in tubulin for advanced melanoma$391,361
R01 · FY2016 · CA
Discovery of tissue-selective, nonhypercalcemic VDR modulators for RA treatment$191,250
R21 · FY2014 · AR
Discovery of tissue-selective, nonhypercalcemic VDR modulators for RA treatment$159,375
R21 · FY2013 · AR
Treatment with KZ-41 and OTP promotes wound healing in a radiation combined injur$356,484
R33 · FY2012 · AI · contact PI
Treatment with KZ-41 and OTP promotes wound healing in a radiation combined injur$365,599
R33 · FY2011 · AI · contact PI
Treatment with KZ-41 and OTP promotes wound healing in a radiation combined injur$386,400
R33 · FY2010 · AI · contact PI
Treatment with KZ-41 and OTP promotes wound healing in a radiation combined injur$248,548
R21 · FY2009 · AI · contact PI
Treatment with KZ-41 and OTP promotes wound healing in a radiation combined injur$10,167
R21 · FY2009 · AI
Treatment with KZ-41 and OTP promotes wound healing in a radiation combined injur$168,560
R21 · FY2008 · AI
Irreversible Nonsteroidal SARMs for Prostate Cancer$293,244
R01 · FY2006 · DK · contact PI
Irreversible Nonsteroidal SARMs for Prostate Cancer$20,541
R01 · FY2006 · DK · contact PI
Irreversible Nonsteroidal SARMs for Prostate Cancer$281,671
R01 · FY2005 · DK
Irreversible Nonsteroidal SARMs for Prostate Cancer$278,376
R01 · FY2004 · DK
Irreversible Nonsteroidal SARMs for Prostate Cancer$295,097
R01 · FY2003 · DK
Small molecule ligand interactions$183,401
U19 · FY2002 · AI
Small molecule ligand interactions$183,401
U19 · FY2001 · AI
Small molecule ligand interactions$183,401
U19 · FY2000 · AI